<div id="readability-page-1"><div><ul> <li>Illumina, Inc. recently reported first-quarter 2026 results showing revenue of US$1,091 million and net income of US$134 million, alongside higher earnings per share versus a year earlier.</li> <li>The company also raised its full-year 2026 revenue outlook to US$4.52–US$4.62 billion and completed a share repurchase of about 7.15% of its stock, signaling management confidence in its business trajectory.</li> <li>We’ll now examine how Illumina’s upgraded 2026 revenue guidance may influence the existing investment narrative and expectations around future earnings.</li> </ul><p>Uncover the next big thing with 25 elite penny stocks that balance risk and reward.</p><h2>Illumina Investment Narrative Recap</h2><p>To own Illumina, you have to believe that next generation sequencing and related clinical applications can keep driving demand for its instruments, consumables and software, despite funding pressures and growing competition. The Q1 2026 results and modest full year revenue upgrade support the near term earnings story but do not materially change the key swing factors, which remain clinical adoption on the upside and research budget and China related weakness on the downside.</p> <p>The most relevant development here is the raised 2026 revenue guidance to US$4.52–US$4.62 billion, a US$20 million uplift at the midpoint. This tighter, slightly higher range gives investors more visibility on the year and sits alongside an already heavy investment cycle in NovaSeq X and multiomics, which many see as central to Illumina’s ability to offset research softness and defend against intensifying competition in high and mid throughput sequencing.</p> <p>But whilst guidance has ticked higher, investors should also be aware of rising regulatory and reimbursement risk in key clinical markets, which...</p> <p>Read the full narrative on Illumina (it's free!)</p><p>Illumina's narrative projects $5.0 billion revenue and $1.0 billion earnings by 2029.</p><p>Uncover how Illumina's forecasts yield a $136.11 fair value, a 7% downside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ac45b0ed-2e31-4654-92b7-31f343d0e66f/chart/quote-price?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ac45b0ed-2e31-4654-92b7-31f343d0e66f/chart/quote-price"/><figcaption>ILMN 1-Year Stock Price Chart</figcaption></figure> <p>Some of the lowest ranked analysts were assuming only about 4.7 percent annual revenue growth to around US$5.0 billion by 2029, so if you are worried about tighter reimbursement and higher compliance costs, this earnings print and guidance raise might prompt you to rethink whether that more pessimistic path still fits the latest numbers.</p><p>Explore 3 other fair value estimates on Illumina - why the stock might be worth 7% less than the current price!</p><h2>Decide For Yourself</h2><p>Don't just follow the ticker - dig into the data and build a conviction that's truly your own.</p><ul><li>A great starting point for your Illumina research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.</li><li>Our free Illumina research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Illumina's overall financial health at a glance.</li></ul><h2>Want Some Alternatives?</h2><p>The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:</p><ul><li>The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.</li><li>Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 33 best rare earth metal stocks of the very few that mine this essential strategic resource.</li><li>Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><div><p>• Dividend Powerhouses (3%+ Yield)<br/>• Undervalued Small Caps with Insider Buying<br/>• High growth Tech and AI Companies</p><p>Or build your own from over 50 metrics.</p></div><p>Explore Now for Free</p></div></div></div>

ILMN

LABU

SBIO

<p>Illumina, Inc. reported Q1 2026 results with revenue of $1,091 million and net income of $134 million, raising its full-year revenue outlook to $4.52–$4.62 billion. The company completed a 7.15% stock buyback, indicating management's confidence. While the upgraded guidance supports near-term earnings, challenges remain, including regulatory risks and competition. Analysts project $5.0 billion revenue by 2029, with a fair value estimate of $136.11, suggesting a 7% downside from the current price. Investors are encouraged to evaluate the data and consider potential risks and rewards in their investment decisions.</p>

Simplywall

Illumina

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

The Bull Case For Illumina (ILMN) Could Change Following Upgraded 2026 Outlook And Major Buyback - Learn Why